June 20, 2025

Gut Bacteria Predict Chemotherapy-Related Heart Damage

Specific gut bacteria correlate with biomarkers indicating increased risk of cardiotoxicity in breast cancer patients before chemotherapy treatment.

Conexiant

June 20, 2025

AI Screening Finds More Aneurysms In Breast MRI

An artificial intelligence system significantly increased detection of thoracic aortic aneurysms during routine breast MRI scans, identifying more cases than standard clinical readings.

Conexiant

June 20, 2025

Does Breast Cancer Lower Alzheimer Risk?

Large Korean cohort study finds breast cancer survivors have an 8% lower Alzheimer disease risk, with radiation therapy showing protective effects.

Conexiant

June 19, 2025

Elevated Cardiac Biomarkers Associated With Increased Cancer Risk

Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American C...

The ASCO Post

June 19, 2025

Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds

Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to h...

The ASCO Post

June 17, 2025

Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC

Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated...

The ASCO Post

June 17, 2025

Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment

In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in oncology, the challenges and rewards of moving to Abu ...

The ASCO Post

June 17, 2025

Anal Cancer Screening Cost-Effective at 35

A large modeling study evaluated the cost-effectiveness, benefits, and harms of anal cancer screening strategies for men who have sex with men living with HIV.

Conexiant

June 17, 2025

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneou...

The ASCO Post